🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Nikkei edges up to fresh 1-year high; chip-related shares jump

Published 10/25/2019, 03:08 PM
Updated 10/25/2019, 03:16 PM
Nikkei edges up to fresh 1-year high; chip-related shares jump
JP225
-
INTC
-
LRCX
-
BIIB
-
SOX
-
TOPX
-
4519
-
4523
-
7735
-
8035
-
6146
-

By Tomo Uetake
TOKYO, Oct 25 (Reuters) - Japan's benchmark Nikkei share
average inched up to a fresh one-year peak on Friday as some
positive earnings from overseas tech companies offset growth
concerns, with semiconductor-related stocks leading the gainers.
The Nikkei average .N225 rose 0.2% to 22,799.81, its
highest closing level since October last year. For the week, it
was up 1.4%, the third consecutive weekly advance.
The broader Topix .TOPX gained 0.3% to 1,648.44, its
highest close in 10-1/2 months.
Semiconductor-related stocks shined after Intel INTC.O
beat Wall Street estimates for third-quarter revenue and profit
and raised its full-year revenue forecast overnight, easing
concerns about slowing demand. Lam Research LRCX.O was the top boost to the Philadelphia
SE Semiconductor index .SOX , which rose 2.5% overnight in New
York trading, after the chip equipment maker forecast strong
results for the December quarter. In Tokyo, the Nikkei heavyweight Tokyo Electron 8035.T and
Screen Holdings 7735.T both climbed 2.6%.
Disco 6146.T soared 11.6% even after the chipmaking
equipment firm reported weak earnings for April-September on a
higher-than-expected dividend as well as hopes the downturn in
orders may bottom out next year. "The market is definitely already thinking beyond this
financial year," said Takeo Kamai, head of executions services
at CLSA in Tokyo.
Elsewhere, Eisai 4523.T enjoyed its stellar run of the
past two days, surging 8.2% after reaching its daily limit-high
on Wednesday and Thursday, as the Japanese drugmaker agreed with
its U.S. partner Biogen BIIB.O to revive plans to seek U.S.
approval for an Alzheimer's treatment. Chugai Pharmaceutical 4519.T added 3.5% as the company
reported a hefty 67% jump in net profit for the
January-September period, thanks to strong sales of hemophilia
drug.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.